You are here

France -
Lévothyrox: le Conseil d'État donne raison au gouvernement dans sa gestion des effets indésirables

Le Conseil d'État a donné raison ce 13 décembre au gouvernement, face à un patient traité avec le médicament Levothyrox , qui avait saisi en urgence la justice administrative pour enjoindre le ministère de la Santé à remettre à disposition des malades l'ancienne formule, dans les 48 heures. Dans sa décision, le Conseil d'État, saisi d'un pourvoi en cassation par le plaignant dont la demande a été rejetée fin septembre par le tribunal administratif de Paris, estime que la ministre de la Santé « n'a pas porté dans sa gestion des effets indésirables de la nouvelle formule du médicament...

France -
Prix des médicaments sans ordonnance : une hausse en trompe l’œil

Selon l’enquête de Familles rurales, le prix des médicaments en vente libre a augmenté de plus de 4 % en 2017. Une hausse démentie par les pharmaciens qui critiquent la méthodologie employée par l’association. Pastilles pour la gorge, comprimés pour les maux de ventre, traitement du bouton de fièvre… Le prix d’une dizaine de médicaments vendus sans ordonnance aurait grimpé de 4,3% en moyenne entre 2016 et 2017, selon le 7ème observatoire des médicaments de l’association Familles rurales. Cette enquête réalisée auprès de 40 pharmacies et 40 sites internet met également en évidence des écarts...

France -
Médicaments conseil : Buzyn veut une « qualité homogène » de dispensation

La ministre de la Santé Agnès Buzyn a indiqué mardi 12 décembre à l’Assemblée nationale qu’une « réflexion sur les leviers à mettre en œuvre pour rendre plus homogène la qualité de la dispensation en officine » allait s’ouvrir, pour ce qui concerne les médicaments de prescription médicale obligatoire et facultative...

Study -
Omalizumab improves efficacy of oral immunotherapy for multiple food allergies

What Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT. Approximately 30 percent of people with food allergy are allergic to multiple foods. Results from the Phase 2 study, funded by the National...

Study -
Screening Mammography Has Little Impact on Advanced Cancer Rates

Screening mammography over a period of 24 years among women age 50 to 74 years has had little effect on reducing rates of advanced breast cancer or mortality from breast cancer in the Netherlands, according to new research. Screening did, however, dramatically increase the detection of early-stage breast cancer, both ductal carcinoma in situ (DCIS) and stage I and, in so doing, contributed to increased rates of overdiagnosis — defined as detection of tumors on screening that would never lead to clinical symptoms in a woman's lifetime. The study, published in the BMJ , concludes that screening...

Discovery -
First U.S. Birth for Woman With Transplanted Uterus Occurs in Texas

For the first time in the United States, a woman with a transplanted uterus gave birth, officials at a Dallas hospital said on Friday. The birth of the healthy baby, whose birth date, sex and weight were not disclosed, was confirmed by a spokesman for the Baylor University Medical Center. The woman who gave birth has asked to remain anonymous, said Craig Civale, spokesman for Baylor and Baylor Scott & White Research Institute. While the birth of a healthy baby by a woman with a transplanted uterus was a medical first in the United States, it follows several childbirths by women with...

Discovery -
New Prostate Cancer Imaging Tracer Improves Detection

Emerging agents for prostate imaging will dramatically improve the ability to determine the location of cancerous legions, which will, in turn, allow the precise targeting of radiotherapy, new research shows. "This is an exciting time in radiology," said Frederik Giesel, MD, Universität Heidelberg in Germany. One agent — 18 F-PSMA-1007 — has some characteristics that are different from other agents, he explained to audiences during his presentation of three different studies at the Radiological Society of North America 2017 Annual Meeting in Chicago. "It has a longer shelf life than the...

France -
Cancer: "la bureaucratie étouffe la recherche!"

Professeur de chirurgie oncologique et directeur général de Gustave Roussy, le plus grand centre anticancer européen, Alexander Eggermont s'élève contre une administration qui étouffe l'innovation au lieu de l'encourager. Une bureaucratisation qui menace la recherche médicale et pénalise les patients eux-mêmes. Alerte sur l’innovation thérapeutique. Alexander Eggermont, patron de l’Institut Gustave Roussy (« Villejuif »), le plus grand centre anticancer européen, accuse l’administration française d’entraver l’innovation, au risque de réduire les chances des patients français de bénéficier des...

Study -
Diabetes and Adiposity Cause 1 in 20 Cancers Worldwide

Nearly 6% of cancers, equating to almost 800,000 cases globally, were attributable to type 2 diabetes and overweight/obesity in 2012, new data show, with adiposity being responsible for almost twice as many cases as diabetes. The study represents the first to estimate the worldwide cancer burden due to diabetes alone and also to diabetes and high body mass index (BMI) combined, say Jonathan Pearson-Stuttard, BMBCh, Imperial College London, United Kingdom, and colleagues in their paper published online November 28 in Lancet Diabetes & Endocrinology . The new figures highlight the...

Study -
Trials show inactivated Zika virus vaccine is safe and immunogenic

Results support further clinical development. The investigational Zika purified inactivated virus (ZPIV) vaccine was well-tolerated and induced an immune response in participants, according to initial results from three Phase 1 clinical trials. Scientists at the Walter Reed Army Institute of Research (WRAIR), part of the U.S. Department of Defense, are developing the vaccine as well as leading one of the trials. WRAIR also is co-funding the trials together with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The results will...

GET IN TOUCH

NEWSLETTER

Make sure you don't miss latest news, stay tuned!